| __timestamp | Apellis Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 461543000 |
| Thursday, January 1, 2015 | 13730311 | 634806000 |
| Friday, January 1, 2016 | 22978599 | 661905000 |
| Sunday, January 1, 2017 | 40303878 | 610753000 |
| Monday, January 1, 2018 | 105285576 | 696328000 |
| Tuesday, January 1, 2019 | 220968770 | 715007000 |
| Wednesday, January 1, 2020 | 299921000 | 628116000 |
| Friday, January 1, 2021 | 420869000 | 628793000 |
| Saturday, January 1, 2022 | 387236000 | 649606000 |
| Sunday, January 1, 2023 | 354387000 | 746773000 |
| Monday, January 1, 2024 | 747184000 |
Infusing magic into the data realm
In the competitive world of biotechnology, investment in research and development (R&D) is crucial for innovation and growth. Over the past decade, BioMarin Pharmaceutical Inc. and Apellis Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, BioMarin consistently outspent Apellis, with R&D expenses peaking at approximately 750 million in 2023, nearly double Apellis's highest expenditure of around 420 million in 2021. This trend highlights BioMarin's robust commitment to innovation, maintaining an average annual R&D investment that is over three times that of Apellis. However, Apellis has shown a remarkable growth trajectory, increasing its R&D spending by over 4000% from 2014 to 2023. This rapid increase underscores Apellis's aggressive push towards innovation, potentially setting the stage for future breakthroughs. As these companies continue to invest in their futures, the biotech industry watches closely to see who will lead the next wave of medical advancements.
Research and Development Expenses Breakdown: Novartis AG vs BioMarin Pharmaceutical Inc.
R&D Insights: How Novartis AG and Apellis Pharmaceuticals, Inc. Allocate Funds
R&D Insights: How Bristol-Myers Squibb Company and BioMarin Pharmaceutical Inc. Allocate Funds
Comparing Innovation Spending: Zoetis Inc. and BioMarin Pharmaceutical Inc.
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Research and Development Expenses Breakdown: Teva Pharmaceutical Industries Limited vs Apellis Pharmaceuticals, Inc.
Summit Therapeutics Inc. or Apellis Pharmaceuticals, Inc.: Who Invests More in Innovation?
BioMarin Pharmaceutical Inc. or Pharming Group N.V.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Viridian Therapeutics, Inc.
R&D Insights: How Apellis Pharmaceuticals, Inc. and Soleno Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.